KRAS GENE AMPLIFICATION IN COLORECTAL CANCER AND IMPACT ON RESPONSE TO EGFR-TARGETED THERAPY
KRAS mutations are the most common oncogenic event in colorectal cancer (CRC) progression and their occurrence is associated with lack of response to anti epidermal growth factor receptor (EGFR) targeted therapies. Using preclinical models and patients’ samples we recently reported that the emergence of KRAS mutations but also KRAS amplification is associated with acquired resistance […]
